Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients Results in Sustained IOP and Medication Reduction
New results of an independent, international study by Glaukos Corporation in Advances in Therapy showed standalone implantation of the iStent inject®Trabecular Micro-Bypass System in eyes with substantial glaucoma disease burden achieved a 42% reduction in mean intraocular pressure (IOP) to 14.6 mmHg and an 82% reduction in mean medications to 0.55 at 3 years postoperative.
The consecutive case series examined 44 eyes and the long-term outcomes of the two-stent iStent inject system as a sole procedure in predominantly primary open-angle glaucoma patients. All procedures were performed at an academic ophthalmology center in Heidelberg, Germany.
3-year postoperative results included:
- 97% of eyes achieved mean IOP ≤18 mmHg vs. 9.1% preoperatively (p<0.0001), and 70% of eyes achieved mean IOP ≤15 mmHg vs. 2.3% preoperatively (p<0.0001).
- IOP decreased ≥20% vs. preoperative measurements in 88% of eyes.
- 61% of eyes were medication free and all eyes maintained or decreased their three-year medication burden vs. preoperative levels.
“While iStent inject has been studied primarily in patients with mild-to-moderate open-angle glaucoma, [the] results add to an emerging body of evidence suggesting that our multiple-stent technology may also be a viable option for patients with more advanced disease, including those who have undergone prior surgeries,” said Thomas Burns, Glaukos president and chief executive officer.
You can read more here.
